Last reviewed · How we verify

Fertility Center of Las Vegas — Portfolio Competitive Intelligence Brief

Fertility Center of Las Vegas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cabergoline Pill Cabergoline Pill marketed Dopamine D2 receptor agonist Dopamine D2 receptor Endocrinology / Reproductive Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  2. University of North Carolina, Chapel Hill · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fertility Center of Las Vegas:

Cite this brief

Drug Landscape (2026). Fertility Center of Las Vegas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fertility-center-of-las-vegas. Accessed 2026-05-17.

Related